The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 06, 2020

Filed:

Jun. 18, 2015
Applicants:

Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts, Heidelberg, DE;

Albert-ludwigs-universitat Freiburg, Freiburg, DE;

Inventors:

Agustin Rodriguez Gonzalez, Heidelberg, DE;

Marcel Schilling, Heidelberg, DE;

Ursula Klingmueller, Heidelberg, DE;

Andreas Raue, Cambridge, MA (US);

Max Schelker, Berlin, DE;

Jens Timmer, Freidburg, DE;

Michael Jarsch, Bad Heilbrunn, DE;

Bernhard Steiert, Freiburg, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G16H 50/20 (2018.01); G16H 50/50 (2018.01); G16B 5/00 (2019.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); G01N 33/80 (2006.01); A61K 38/18 (2006.01); A61K 9/00 (2006.01); G01N 33/72 (2006.01);
U.S. Cl.
CPC ...
G16H 50/20 (2018.01); A61K 9/0019 (2013.01); A61K 38/1816 (2013.01); G01N 33/5044 (2013.01); G01N 33/6893 (2013.01); G01N 33/721 (2013.01); G01N 33/80 (2013.01); G16B 5/00 (2019.02); G16H 50/50 (2018.01); G01N 2800/222 (2013.01);
Abstract

An integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model calculates the binding behavior of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.


Find Patent Forward Citations

Loading…